Saturday 17 October 2026
Export DMRA’s income statement to Excel — free account
Galecto, Inc.
DMRA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 85.0% and free cash flow fell 877.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
18.42
0.32
−1.71%
Follow DMRA
Galecto, Inc. (DMRA) P/E ratio
Galecto, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 2.5× (June 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 2.5×
Ten-year median
0.0×
Current reading's percentile
87
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LBRX LB Pharmaceuticals Inc compare | n/m |
| DMRA Galecto, Inc. | n/m |
| VOR Vor Biopharma Inc. compare | n/m |
| BCAX Bicara Therapeutics Inc. compare | n/m |
| DRTS Alpha Tau Medical Ltd. compare | n/m |
| TSHA Taysha Gene Therapies, Inc. compare | n/m |
| SNDX Syndax Pharmaceuticals, Inc. compare | n/m |
| NBTX Nanobiotix S.A. - Sponsored ADR compare | n/m |
| REPL Replimune Group, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)